FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)

On Kalshi, this market is priced through a continuous double auction, meaning traders can buy and sell contracts representing their beliefs about the outcome. The price of a contract reflects the probability of that outcome occurring. On Kalshi, prices reflect that venue's order book, liquidity, and how traders price the outcome right now. As more traders participate and new information becomes available, the price adjusts to reflect the collective assessment of the market. The current price indicates what traders are willing to pay for exposure to the potential FDA approval of Bepirovirsen.

This market resolves around Jan 1, 2027, with the outcome confirmed once the event is verifiable from credible public reporting. Specifically, the resolution will be based on the FDA’s official announcement regarding the approval or rejection of Bepirovirsen. The market will reflect whether the FDA has granted full approval for the drug, based on their publicly available decision. Traders should monitor official FDA communications for the definitive outcome of this market.

Several key events could significantly impact this market. Positive or negative updates from GlaxoSmithKline regarding clinical trial results or the submission of data to the FDA would likely cause price fluctuations. Any announcements from the FDA regarding the review process, such as granting priority review or requesting additional information, would also be influential. Unexpected safety concerns or efficacy data emerging from independent sources could also move this market, as would broader news related to the treatment of chronic hepatitis B.